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Purpose: In 2013, during a recent heroin-assisted treatment trial, participants in heroin-assisted treatment (HAT)
decreased signiﬁcantlymore their street heroinuse thanparticipants in oralmethadone treatment. After the trial,
HAT was discontinued. To examine whether the treatment beneﬁts were sustained three months after the trial,
the use of street heroin by the participants was analyzed in a follow-up study.
Results: At the follow-up assessment, street heroin use increased in the experimental group. The two groups no
longer showed a signiﬁcant difference (p = 0.55) in the level of street heroin use.
Conclusion: A predetermined and forced end of HAT was followed by a signiﬁcant increase in the level of street
level use.© 2016 Elsevier Inc. All rights reserved.1. Introduction
To help heroin-dependent individuals, Belgium - alongside 89% of
European countries - offers oral methadone treatment (OMT) (World
Health Organization, 2010). However, a proportion of heroin-
dependent persons continue to pursue their street heroin use while in
OMT. For these individuals, a model of heroin-assisted treatment
(HAT) was developed in Switzerland in the nineties (Khan, Khazaal,
Thorens, Zullino, & Uchtenhagen, 2014; Perneger, Giner, del Rio, &
Mino, 1998; Rehm et al., 2001). In HAT, patients receive medically pre-
scribed diacetylmorphine (DAM) under the supervision of nurses, in an
outpatient setting (Demaret, Lemaître, & Ansseau, 2012; Ferri, Davoli, &
Perucci, 2011). HAT has showed greater efﬁcacy than OMT (Ferri et al.,
2011). After the trials, a prolonged HAT was associated with sustained
improvement (Blanken, Hendriks, Van Ree, & Van Den Brink, 2010;
Guttinger, Gschwend, Schulte, Rehm, & Uchtenhagen, 2003; Oviedo-
Joekes, March, Romero, & Perea-Milla, 2010; Verthein et al., 2008).l methadone treatment; DAM,
Social Sciences (Université de
lgium. Tel.: +32 4 366 31 58;
t).In Belgium, HAT was accepted and funded by the federal govern-
ment but only for a period of 12 months and as a clinical trial because
prescribing DAM for heroin dependence was (and still is) illegal. This
clinical trial has been conducted in Liège, a city where heroin depen-
dence has been particularly problematic. In the urban area of Liège,
OMT is widely available and people can freely choose their physician
or their treatment centre. In 2007, 3000 people in this area were
heroin-dependent, compared to a population of 500,000 inhabitants
(Demaret, Herné, Lemaître, & Ansseau, 2011).
During the randomized controlled trial, street heroin use decreased
signiﬁcantly more in the experimental group with HAT compared to
the control group with OMT (Demaret et al., 2015). The modalities of
our trial were comparable to the other trials and we included the
same target group of persons with heroin dependence and regular
street heroin use in spite of a current or previous drug treatment
(Ferri et al., 2011; Haasen et al., 2007; March, Oviedo-Joekes, Perea-
Milla, Carrasco, & PEPSA Team, 2006; Oviedo-Joekes et al., 2008;
Perneger et al., 1998; Strang et al., 2010; van den Brink et al., 2003).
The main difference in our trial was the duration of HAT (limited to
12 months), which was not based upon scientiﬁc reasons. The only
other trial with a predetermined end of HAT was the Canadian one. A
follow-up study of this trial showed that street heroin use rose after
the end of HAT, particularly for the group of participants who did not
transition voluntarily from DAM to oral methadone (Oviedo-joekes
73I. Demaret et al. / Journal of Substance Abuse Treatment 69 (2016) 72–75et al., 2014). In the Dutch trial, HAT was also discontinued after 12
months, but only during 2 months. This also had a negative impact:
82% of the participants who were completers and responders deterio-
rated substantially at the endof this discontinuation. After this interrup-
tion however, HAT could be pursued with no predeﬁned end point for
the participants who deteriorated after the discontinuation (van den
Brink et al., 2003).
In this paper, we report the results of a follow-up study and evaluat-
ed whether the decrease of street heroin use was sustained three
months after the Belgian trial.2. Methods
2.1. Design
TADAM (Treatment Assisted by DAM) was an open label, random-
ized controlled trial; it began in January 2011 and ended in January
2013. The Ethics Committee of the University of Liège approved this
trial (number 2009/189) on March 16, 2010, including a follow-up
after 3 months. After the end of the trial (i.e. at 12 months from treat-
ment start) HAT was stopped in the experimental group and the most
appropriate treatment at the time of the transition was offered to each
participant. The detailed method and inclusion criteria were as de-
scribed previously (Demaret et al., 2015).2.2. Assessments
Every three months from baseline to 15 months, street heroin use
and cocaine use were measured by the number of days of use during
the previous month, using the European Addiction Severity Index
(Kokkevi & Hartgers, 1995). During each assessment, participants also
provided a urine sample. In urinalysis (ultra-high-pressure liquid chro-
matography coupled with mass spectrometry), street heroin use was
indicated by the detection ofmeconin, ametabolite of an opiumconstit-
uent (noscapine) that is not found in DAM. The presence of
benzoylecgonine, a metabolite of cocaine in the sample, revealed co-
caine use. In case of discrepancy between self-reported and toxicologi-
cal data, we replaced the self-reported value by a value based on prior
use. At each assessment, physical healthwasmeasured by theMaudlsey
Addiction Proﬁle – Health Symptoms Scale (MAP-HSS) (Marsden et al.,
1998); mental health by the total score of the Symptom Check-List
(SCL–90–R) (Gosselin & Bergeron, 1993; Pellet, 1997); criminal involve-
ment was characterized by self-reported facts committed or experi-
enced as a victim, during the previous month (Ansseau et al., 2005).
At each assessment, participants who were not (or were no longer) in
the HAT centre received a compensation (between 15 and 60 euro de-
pendingon thepresence ofmedical examination, blood andurine sample).
The research team remained independent from the treatment staff.Table 1





T0 T03 T06 T09 T12 T15 Pa
Street heroin
useb
DAM 25 6 5 4 8 14 p = 0.00094
METH 28 18 17 18 16 17
Cocaine useb DAM 3 2 3 2 1 2 p = 0.83
METH 5 5 3 4 2 3
Criminal
involvementb
DAM 9 2 3 2 1 2 p = 0.35
METH 8 4 4 5 6 5
MAP-HSS - total
score
DAM 18 13 15 13 16 13 p = 0.0195
METH 19 17 17 17 17 18
SCL-90-R - total
score
DAM 109 75 70 70 71 71 p = 0.056
METH 110 98 92 95 86 94
a p for mixed-design analyses of variance (ANOVA).
b Self-reported data (number of days in past month) complemented with toxicologica
analysis or registered criminal proceedings.2.3. Statistical analysis
Mixed-design analyses of variance (ANOVA), with the experimental
group (two levels) as a between-subject factor and time post-inclusion
(six levels: baseline, 3, 6, 9, 12 and 15 months post-inclusion) as a
within-subject factor, were used for the analyses of continuous data
(for self-reported value). The ANOVAs were followed by Newman–
Keuls post-hoc comparisons to assess between-group differences. To
analyze the level ofmeconin, Friedman tests for non-parametric repeat-
ed measures comparisons were carried out on both groups separately.
Non-parametric Spearman correlations were used to examine the asso-
ciation between urinalysis and self-reported values on street heroin use
at each assessment. Statistical analyses were performed with
STATISTICA 10. Statistical signiﬁcance was set at p b 0.05. Only partici-
pants seen at each assessment were included in these analyses.3. Results
3.1. Participants' characteristics and follow up
Participants' characteristics were described previously (Demaret
et al., 2015). Among the 74 participants included in the trial, 13were ex-
cluded from this analysis: in the experimental group, 1 refused to be
interviewed, 1 had died and 3 could not be reached at an intermediate
assessment; in the control group, 5 refused to be interviewed and 3
could not be reached at an intermediate assessment. 61 (82%) partici-
pants were interviewed at each assessment: 31 in the experimental
group and 30 in the control group. Of these 61 participants, 2 (one in
each group) could not provide a urine sample (they were interviewed
in prison) and 2 (both in the experimental group) reported no street
heroin use but gave a positive urine sample. The retention rate in substi-
tution treatment was higher for the participants in the experimental
group, but the difference was not signiﬁcant: 30 (97%) versus 26
(87%). The 5 other participantswere neither in a substitution treatment,
nor abstinent.
3.2. Evolution of the efﬁcacy indicators
Table 1 shows the evolution of efﬁcacy indicators frombaseline to 15
months for the 61 patients. Compared to baseline, the decrease of street
heroin use at the 15-month assessment was signiﬁcantly higher in the
experimental group than in the control group (p b 0.001). MAP-HSS
scores also indicated a signiﬁcantly higher improvement in the experi-
mental group (p b 0.05). The other efﬁcacy indicators revealed no signif-
icant difference between both groups.
3.3. Other analyses of street heroin use
Newman–Keuls post-hoc tests showed signiﬁcant differences of street
heroin use between the two groups at each assessment (Fig. 1), except at
baseline and at the 15-month assessment (p = 0.55). Newman–Keuls
post-hoc-tests also showed a signiﬁcant increase of street heroin use in
the experimental group between the 12 and 15-month assessments
(p = 0.0052). Mean levels of meconin (Fig. 2) improved signiﬁcantly in
the experimental group (χ2(5)= 35.01; p b 0.00001) but not in the con-
trol group (χ2(5) = 5.59; p = 0.35). Non-parametric Spearman correla-
tions between self-reported values and meconin levels were signiﬁcant
except at baseline (data not shown).
4. Discussion
During the trial, participants in the experimental group showed a
decrease of street heroin use signiﬁcantly more important than in the
control group, as in ﬁve other trials (Haasen et al., 2007; March et al.,
2006; Oviedo-Joekes et al., 2009; Perneger et al., 1998; Strang et al.,l
Time post-inclusion (months)





























Fig. 1. Improvement in street heroin use at each assessment (self-reported data corrected
by toxicological analyses; ** = p b 0.01). Vertical bars represent the standard error of the
mean value.
74 I. Demaret et al. / Journal of Substance Abuse Treatment 69 (2016) 72–752010) and, as in other trials, this effect was conﬁrmed by urinalysis and
cocaine use did not increase. Their scores on the physical (MAP-HSS)
andmental (SCL-90-R) health questionnaires also improved signiﬁcant-
ly more after 12 months, as in other trials (Demaret et al., 2015). At the
follow-up assessment, only street heroin use and scores on the MAP-
HSS revealed signiﬁcant improvement in the experimental group. Co-
caine use and criminal involvement were low in both groups and the
difference of evolution between the groupswas never signiﬁcant during
or after the trial.
However, after the end of HAT, street heroin use signiﬁcantly in-
creased in the experimental group and the difference between the
groups was no longer signiﬁcant with the Newman–Keuls post-hoc
tests at the follow-up assessment. In the follow-up studies of other tri-
als, this increase in street heroin use was not found for individuals
who could continue HAT. On the contrary, participants in long-term
HAT reported less street heroin use than those who stopped HAT
(Blanken et al., 2010; Guttinger et al., 2003; Oviedo-Joekes et al., 2010;
Verthein et al., 2008). Furthermore, participants who stopped HAT in-
voluntarily showed a particularly important increase of their street her-
oin use in comparison with participants who stopped voluntarily
(Oviedo-joekes et al., 2014).
Theworsening of participants' situations following discontinuation of
HAT compared to their situations during treatment further supports the
idea that a predetermined and abrupt end of HAT leads to a loss of ben-
eﬁts gained during treatment (Demaret et al., 2015). Given this, a forced
end of HATwithout therapeutic justiﬁcation can be seen as ethically dis-
putable, even after a 12-month treatment. This deterioration justiﬁes the
refusal of heroin-dependent individuals to enter the trial during the re-
cruitment process because of the predetermined end of HAT (DemaretFig. 2. Levels of meconin at each assessment based on urinalysis.et al., 2014). These refusals could have been a cause of the lack of
power of our primary outcome analysis (Demaret et al., 2015).
Our study limits were the relatively low number of participants and
the fact that our trial and the follow-up study were not designed to
assess the effect of the forced end of HAT after 12months. Nonetheless,
our conclusions were supported by the results of other trials as
seen above.
5. Conclusion
HAT is more effective than OMT for decreasing street heroin use for
heroin-dependent individualswho pursue street heroin use in spite of a
current or previous OMT. However, threemonths after a predetermined
end of HAT (i.e. without a spontaneous demand by the patient), the use
of street heroin increased again to reach levels very close to those ob-
served in the control group. Therefore, HAT should be offered as an
open-ended treatment as recommend by the WHO for other opioid
treatment (World Health Organization, 2010) and the end of treatment
should be a clinical decision based on the evolution of the patient.
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